October 2021

Column

Editor's Page

Early Impressions From OCPC 2021

10/20/2021

Winston Wong, PharmD, Editor-in-Chief

Winston Wong, PharmD, Editor-in-Chief, discusses the features in this issue, which cover new technology that may help guide treatment decisions for patients with metastatic breast cancer and differences in referral patterns and treatment...

Winston Wong, PharmD,...

10/20/2021

Journal of Clinical Pathways

Clinical Pathways GPS

Medicare Drug Benefit ... The ABCDs

10/20/2021

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.

Richard G. Stefanacci, DO, MGH,...

10/20/2021

Journal of Clinical Pathways

Trending From ACCC

Measurable Residual Disease Testing Implementation Roadmap for Patients With ALL

10/20/2021

American Association of Community Cancer Centers

The Association of Community Cancer Centers developed an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for adult patients with ALL.

The Association of Community...

10/20/2021

Journal of Clinical Pathways

Pharma Insights

COVID-19 and Diabetes: Strategies to Catch Up

10/20/2021

Cynthia Miller, MD, MPH, FACP

Cynthia Miller, MD, MPH, FACP, discusses initiatives pharmaceutical companies can employ to assist physician groups and payers in adding appropriate pharmacologic therapies to reduce the burden of COVID-19 on persons with diabetes.

Cynthia Miller, MD, MPH, FACP,...

10/20/2021

Journal of Clinical Pathways

Rajiv Panikkar, MD, Geisinger Cancer Institute Chair

Sponsored

Elsevier Partner Spotlight

Increasing Physician Awareness of Clinical Trials Through Oncology Pathways

10/20/2021

Rajiv Panikkar, MD, Geisinger Cancer Institute Chair

Rajiv Panikkar, MD, Geisinger Cancer ...

Rajiv Panikkar, MD, explains how embedding clinical trials into the oncology pathways at Geisinger’s Cancer Institute has increased awareness of their clinical research program.

Rajiv Panikkar, MD, explains how...

10/20/2021

Journal of Clinical Pathways

Department

Letters to the Editor

Atezolizumab Plus Bevacizumab Is Cost-Effective for Advanced HCC When Utilizing Biosimilars

10/20/2021

Aimee Ginsburg, PharmD, BCPS

Leslie Busby, MD

Kaci Dominguez, PharmD

Josh Howell, PharmD, BCOP

Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.

Aimee Ginsburg, PharmD, BCPS,...

10/20/2021

Journal of Clinical Pathways

Feature

Research Reports

Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States

10/20/2021

Poorni M. Manohar, MD

Hannah M. Linden, MD

Josh A. Roth, PhD, MHA

Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.

Poorni M. Manohar, MD, et al...

10/20/2021

Journal of Clinical Pathways

From the Field

Referral Patterns and Treatment Preferences in Patients With Advanced Prostate Cancer: Differences Between Medical Oncologists and Urologists

10/20/2021

Ajeet Gajra, MD, FACP

Skyler Hime Rupard, MS

Yolaine Jeune-Smith, PhD

Bruce Feinberg, DO

Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer

Ajeet Gajra, MD, FACP, et al...

10/20/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

October 2021

Column

Department

Feature

Current Issue

Special Reports

Subscribe

October 2021 Volume 7 Issue 8

Specialties

Events

Year Round Education

HMP Global Products